chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Platelet count is up to 97. Yes it has been lower before that not as low as the 92 except for when I was on blood thinners in the hospital in 2019; This spontaneous case was reported by a consumer and describes the occurrence of PLATELET COUNT ABNORMAL (Platelet count is up to 97. Yes it has been lower before that not as low as the 92 except for when I was on blood thinners in the hospital in 2019) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PLATELET COUNT ABNORMAL (Platelet count is up to 97. Yes it has been lower before that not as low as the 92 except for when I was on blood thinners in the hospital in 2019). At the time of the report, PLATELET COUNT ABNORMAL (Platelet count is up to 97. Yes it has been lower before that not as low as the 92 except for when I was on blood thinners in the hospital in 2019) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2019, Platelet count: inconclusive (Inconclusive) been lower before that not as low as the 92 except for when the patient was on blood thinners in the hospital in 2019.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication are reported.  Treatment information is not reported
Swollen lymph nodes under right arm pit; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the right arm on 23Feb2021 at 15:30 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN) 5 mg (milligram) 1x day and linagliptin (TRADJENTA) tablet 5 mg; both for unknown indications from unknown dates and unknown if ongoing.  On 09Mar2021 at 02:00, the patient experienced swollen lymph nodes under right arm pit. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph nodes under right arm pit was unknown at the time of the report.  No follow-up attempts are needed. No further information is expected.
ITCHY THROAT AND ARMS, SUDDEN ONSET OF HEADACHE, ANXIETY.
Developed injection site reaction to COVID 19 vaccine on 8th day after vaccination - vaccine on 1/23/21, redness/swelling/etc. developed on 1/31/21.   Site appeared properly cleaned with alcohol prior to the injection and there was no noticeable reaction prior to 1/31/2021.
Patient reported  feeling mild scratchy throat 17 minutes after receiving 2nd dose of Moderna vaccine, she denied difficulty breathing or difficulty swallowing. Denied chest pain, palpitations, dizziness, pruritus or any other symptoms. Patient reported scratchy throat resolved almost instantly and without intervention, she denied any other symptoms. BP 136/88, HR 75, SpO2 100 % room air. Patient denied reaction to first dose of vaccine given on 2/26/21 and stated she only experienced mild pain at injection site. She was evaluated by Nurse Practitioner; patient was alert and oriented, calm and in no distress. She reported feeling well. Patient agreed to be observed for an additional 15 minutes. Patient reported feeling well after observation and asymptomatic and was discharged home in stable condition.
Information has been received from a 26 year old female licensed practical nurse with no pertinent medical history and no known allergies or adverse drug reactions reported who on 07-AUG-2006 was vaccinated intramuscularly with a 0.5 ml dose of HPV rLi 6 11 16 18 VLP vaccine (yeast) (Lot#653650/0696F).  There were no concomitant medications reported.  The licensed practical nurse reported that she received HPV rLi 6 11 16 18 VLP vaccine (yeast) in her deltoid from a pre-filled syringe.  It was reported that when the injection was completed, the nurse administering it "let go of the plunger before taking it out of her arm" and the "spring shot the syringe out of the arm like a dart".  It was reported that "some fluid leaked out of her arm".  The licensed practical nurse reported that it "stung a little when the vaccine was administered" and then resolved in a few moments.  The area of the spill was cleansed with alcohol.  The patient sought unspecified medical attention.  There were no laboratory diagnostic studies performed.  At the time of this report, the patient had recovered from the events.  Additional information has been requested.
Within 5 minutes of receiving the dt shot in his thigh, the patient broke out is a red rash that started on his neck.  Over the next 10 minutes the rash spread to his face, went down his arms to his hands, and started down his back.  It stopped spreading after about 20 minutes.  The rash stayed on the patient for about 2 hours.
My son got meningitis vaccination about Jul05 and few week later he started to have severe pain in his lower back and pain and weakness in his legs. He is doing more physically therapy and exercises inorder to improve.
On 12/5/2021 The day after her 2nd dose in the morning at 7:00am my daughter developed a lazy eye in her right eye. I witnessed this happening about 5 to 6 times on 12/5/2021. It was sporadic and not constant.  Her right eye would turn in towards her nose. Her left eye was behaving as normal.
04/04/03: Vomited early morning; 04/06/03: Hives on cheeks and itching, diarrhea, fever; 04/11/03: Fever 103F, same symptoms and joint aches, went to MD told viral; 04/18/03: Fever 103F, can't walk, weak, diarrhea, hives, ER, told viral; 04/21/04: Hospitalization; 04/26/04: Hospitalization, told had juvenile arthritis.    Nurse follow up on 05/18/04 states: "ADD: juvenile rheumatoid --   arthritis rheumat arthritis .Delete: arthritis."  06/09/2005: patient has not recovered.  Patient has juvenile rhuematoid arthritis, autoimmune hemolytic anemia.  Symptoms include anemia, joint pain to the point sometimes patient is unable to walk.
Within a few hours after receiving the second dose of Pfizer COVID-19 vaccine, suddenly experienced fever, chills, full body shaking, headache, body aches, nausea, and fatigue. This lasted for 3 days.
tested positive again for covid.; tested positive again for covid.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26Mar2021 as dose 1, single (Batch/Lot number: unknown), on 16Apr2021 as dose 2, single (Batch/Lot number: unknown) and on 28Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 29 years for covid-19 immunisation. The patient's relevant medical history included: "heart disease" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "tested positive again for covid.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Negative; (unspecified date) Unknown results, notes: COVID 19 Treatment; (Jun2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 included Paxlovid started on 26May2022 to 30May2022. Clinical course: Paxlovid prescribed. tested negative after taking it for 5 days and isolating. symptoms were gone too. then 5 days: different symptoms (congestion, cold symptoms). She thought it was a cold but tested positive again for covid. was this a rebound effect from taking paxlovid same thing happened to her father.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
In approxmately 3 days severe pain on chest (left side) and breast and back and then diagnosed with shingles in the emergency room on 11/21/2010
reorted on 10/29 that she received a flu shot 10/22 @ employee flu clinic. Had soreness and swelling that afternoon. Next day shes said she had swelling @ site; on 10/24 noticed swelling in L neck area. Had some soreness in that area, but not a present. Still has minior swelling in that area. To make appointment with PMD. No fever after flu shot or at present.
This is in follow-up to report (s) previously submitted on 10/12/2007. Information has been received from the mother of an 18 year old female who on 21-DEC-2006 was vaccinated with the first dose of GARDASIL, the second dose on 27-FEB-2007, and the third dose on 19-JUL-2007. On 21-AUG-2007 the patient inadvertently received a fourth dose of GARDASIL. After receiving the fourth dose, the patient developed acne on her face. Unspecified medical attention was sought. No laboratory diagnostic studies were performed. Follow up information states she has not yet gotten her period. The mother reported that her daughter never had irregular periods prior to the vaccination. As of 28-SEP-2007 the patient had not recovered. No product qualtity complaint was involved. The patient's twin sister also received 4 doses of GARDASIL and developed acne on her face (WAES0710USA00553). Additional information has been requested.
Pt received her vaccine 10/3 when leaving pt could not move her arm. Pain has only gotten worse. Pt has been to her physician, he said my have hit a tendon Pt went to the MD's office
Case previously recorded as MA2009-3739. Initial case report received from a nurse, via Novartis Medical Communication, on 10 NOV 2009. A 3-year-old male patient was vaccinated with 0.5 ml of S-OIV FLUVIRIN (batch no. 100814) i.m. on 05 NOV 2009, an off-label indication. No adverse event was reported. MedCom reference no.: NA09-007690.
Mom calls and reports that Patient developed a knot and swelling to the right arm on 7/15/17.
Patient came in with 2 red bumps where vaccines were given. Very warm to touch and very tender on left thigh.
Patient had pimple like reaction on opposite side of body. 1 pimple like dot on middle arm, midriff, calf and toe and they itched really bad and appeared about a week after the injection. They are now going away but are not completely gone.
I began having pain in the lymph nodes in my right under arm, then started experiencing stiffness in my neck, and today noticed a swollen node above my collar bone on the right as well. It is painful to touch and is radiating pain in my throat, right ear, and neck around the node.
onset 6hr after vaccine of ocnstant band-like pulsatile headache (with occasional short-lived photophobia), severe generalized body aches, and fatigue, together of enough severity to keep him out of work for 4 days
soreness 4-5 days - then started to hurt. Got worse daily. Sharp pain then muscle like cramping all over upper arm. Waking me at nite several times. Hurt to move arm or shoulder. Xray + ultrasound asst. steroid inj. Some better today - Has been over 9 weeks
started having bladder infections; she is dehydrated, she is not drinking enough; noticed she wasn't as thirsty as usual; This spontaneous case was reported by a consumer and describes the occurrence of THIRST DECREASED (noticed she wasn't as thirsty as usual), CYSTITIS (started having bladder infections) and DEHYDRATION (she is dehydrated, she is not drinking enough) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ALPRAZOLAM (XANAX) for Anxiety, LISINOPRIL for Diabetes, PIOGLITAZONE HYDROCHLORIDE (ACTOS) and ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced THIRST DECREASED (noticed she wasn't as thirsty as usual). In July 2021, the patient experienced CYSTITIS (started having bladder infections) and DEHYDRATION (she is dehydrated, she is not drinking enough). The patient was treated with CEFUROXIME AXETIL (CEFTIN [CEFUROXIME AXETIL]) for Adverse event, at an unspecified dose and frequency. At the time of the report, THIRST DECREASED (noticed she wasn't as thirsty as usual), CYSTITIS (started having bladder infections) and DEHYDRATION (she is dehydrated, she is not drinking enough) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications also included steroid shot occasionally for joints, Tylenol for chronic eye pain.   This case was linked to MOD-2021-385802 (Patient Link).
This spontaneous report as received from a pharmacist via a company representative refers to an unknown age female patient. Pertinent medical history, drug allergies or reaction were not reported. In approximately December 2013/January 2014, reported as "within the last month", the patient was vaccinated with ZOSTAVAX, lot # J005849, expiration date: 17-AUG-2014, subcutaneous. Concomitant medication was not reported. On an unknown date, the patient experienced mild local reaction at injection site. The patient developed an itchy, red, tender "knot" with swelling at site of ZOSTAVAX injection. The patient sought medical attention. The patient's symptoms resolved within 4 - 5 days. Causality was not reported. This case is linked to the same reporter MARRS # 1401USA003340 and 1401USA003341. Additional information has been requested.
Fever; Chills; Tremor; vomiting- Information has been received from Wyeth-Ayerst Research, MCN: Ho5182521Dec2000, regarding the patient concerned, a 15 month old caucasian male, with an unspecified drug hypersensitivity, was vaccinated with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live second generation 0.5 ml subsutaneously on 11 OCT 1996.  In the evening that day, the baby experienced fever, emesis and shakinese.  In follow up, the nurse reported that the baby experienced and episode of chills, shaking, and emesis, The nurse noted that the patient's father had reported, on 28 July 2000, that his family was frightened.  A neighbor who was a nurse was called to come over.  No treatment was necessary and the situation resolved.  The baby was ok the next day.  No definite seizure was identified.  No further details was provided.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 38 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 18Dec2021 11:30 (Lot number: Fl3197) at the age of 38 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "IgA nephropathy" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Moderna (Dose Number: 2, Batch/Lot No: 026b21a, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 13Apr2021, for Covid-19 immunization; Moderna (Dose Number: 1, Batch/Lot No: 008c21a, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 11May2021, for COVID-19 immunization.The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 18Dec2021 11:30, outcome "unknown", described as "Dose 1: Moderna; Dose 2: Moderna"; IMMUNISATION (non-serious) with onset 18Dec2021 11:30, outcome "unknown", described as "Booster"; MIGRAINE (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Migraine"; LYMPHADENOPATHY (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Swollen lymph node in underarm"; FATIGUE (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Extreme fatigue"; DIZZINESS (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Light headedness"; NAUSEA (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Nausea"; DECREASED APPETITE (non-serious) with onset 19Dec2021 08:00, outcome "recovering", described as "Loss of appetite". Therapeutic measures were not taken as a result of migraine, lymphadenopathy, fatigue, dizziness, nausea, decreased appetite.Additional Information:Prior vaccination within 4 weeks was reported as none. Prior vaccination patient was not diagnosed with COVID-19 and since the vaccination the patient had not been tested for COVID-19.No follow-up attempts are possible. No further information is expected.
Information has been received from a registered nurse, who was told by one of her patients that a female patient who an unknown date was vaccinated with a dose of GARDASIL vaccine (yeast). Subsequently, the patient developed chronic fatigue syndrome. At the time of reporting, the patient's chronic fatigue syndrome persisted. There was no product quality complaint. This is one of several reports provided by the same source. Additional information has been requested.
Facial swelling; Facial rash; Allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING FACE (Facial swelling), RASH (Facial rash) and HYPERSENSITIVITY (Allergic reaction) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product NALTREXONE (VIVITROL) for Alcoholism.    Concurrent medical conditions included Alcoholism.   In April 2021, the patient received dose of NALTREXONE (VIVITROL) (Intramuscular) 380 milligram. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced SWELLING FACE (Facial swelling), RASH (Facial rash) and HYPERSENSITIVITY (Allergic reaction). At the time of the report, SWELLING FACE (Facial swelling), RASH (Facial rash) and HYPERSENSITIVITY (Allergic reaction) outcome was unknown.            Patient was still taking vivitrol 380 mg intramuscularly in gluteal region every four weeks.  Concomitant drugs were not reported. Treatment details were not given.
CLL lymphoma; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot Number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Patient reported that she was vaccinated with the Pfizer (COVID) vaccine, had the 2 vaccines, had CLL lymphoma, had been tested twice by Oncologist and had negative antibodies. And Oncologist would like patient to take a third vaccine. Patient asked if there was any way patient can get that vaccine. No other additional information was provided. The patient underwent lab tests and procedures which included antibody test: negative on unspecified date. Clinical outcome of event was unknown.  Information on the lot/batch number has been requested.
pt was fussy-began to cry so hard that had difficulty getting breath unconsolable; pt crying & whimpering last 3.5 hrs; MD called pt seen;
Pt recvd Hep B vax on 19MAY92 & exp delayed anaphylactic reaction; seen by MD no further details were provided;
Pt received SPX on 02 Oct. 13 on 09 Oct 13 pt noted redness around left eye and rash on upper lid. Pt went to clinic on 11 Oct 13 with no pain or visual problems. Grouped blisters noted by provider on upper eye lid. Referred to another clinic and to ER. Was confirmed to be autoinoculation form SPX. She was given VIROPTIC drops and valcyclovir.
She returned to the vaccine clinic approximately 35 minutes after having received her vaccine. She complained of feeling dizzy and nauseated. She was placed on vs monitor. BP 128/79, HR 82, O2sat 100%. 8:35am BP 142/101, HR 82, O2sat 100%. She stated that her chest felt funny like her heart beating different. Monitor with NSR. Code green called. She was taken to Emergency Department via stretcher. VS upon leaving vaccine clinic 155/96, 90, O2sat 100%.
Left arm swollen from shoulder down to elbow, red hot to touch and painful started 6/13/2018 On 6/14/2018 was given KEFLEX 500mg TID x 10 days, elevation, ice and Ibuprofen.
Pregnant; Flu like symptoms; Pain; Fever; Tiredness; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of PREGNANCY (Pregnant), INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN (Pain), PYREXIA (Fever) and FATIGUE (Tiredness) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 25-May-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN (Pain), PYREXIA (Fever) and FATIGUE (Tiredness). On 18-Jun-2021, the patient experienced PREGNANCY (Pregnant). At the time of the report, PREGNANCY (Pregnant), INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN (Pain), PYREXIA (Fever) and FATIGUE (Tiredness) outcome was unknown.            Concomitant medication were not reported by reporter.  Treatment information was not provided by reporter.   This case was linked to MOD-2021-235507 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jun-2021: No new information. On 22-Jul-2021: Non-significant information, reporter's contact details added.
Information has been received from a licensed practical nurse (L.P.N.) referring to two patients of unknown age and gender. No relevant medical history or concurrent conditions were reported. On unknown dates, the patients were vaccinated with improperly stored PROQUAD (dose, route, lot# and expiration date were not reported). No adverse symptoms were reported. Additional information has been requested.
Information has been received from a physician concerning a male who was vaccinated IM with a dose of Zostavax (Oka/Merck).  The patient presented to the office a couple of days after receiving the Zostavax with a rash and the physician diagnosed him with shingles.  At the time of the report the patient's outcome was not reported.
I suffered a miscarriage at 7 weeks 4 days. Miscarriage occurred on 1/23/21.  Vaccination 1 was on 12/26/20 & Vaccination 2 was 1/12/21
Pt seen by pvt MD dx w/urticaria on hands 9 days post vax;
A 32 y/o male was seen at hospital on 11/16/2003. Anthrax adverse reaction. Date of onset: 11/13/03. Localized erythema and edema involving the subcutaneous tissue of the left posterior arm. Pain and tenderness extended to the shoulder, elbow and fingertips. Strength and sensation noted within normal limits upon exam. Motor skills are intact. Labs: none. Global headache.